New Zealanders now have funded access to a global standard of care treatment for a form of liver cancer, Hepatocellular Carcinoma (HCC), which, unlike many other cancers has a rapidly increasing rate ...
Developed by Johnson & Johnson, guselkumab (GUS) is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.
Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback